Skip to main content
. 2012 Jun;18(6):825–834. doi: 10.1177/1352458512438454

Figure 2.

Figure 2.

Prospective clinical trials for HSCT in MS. Choice of trial design. BAAT, best available and approved treatment; DMA, disease-modifying agent; HSCT, haematopoietic stem cell transplantation.